HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supplement, Drug Co-Packaging Potential Could Be Clipped In FDA Proposed Rule

This article was originally published in The Rose Sheet

Executive Summary

Innovus Pharmaceuticals is among the firms offering supplements and OTC drugs sold together, an option CRN encourages FDA to allow. FDA will determine on a case-by-case basis whether co-packaged OTCs and supplements already available are in violation of a proposed rule on drug co-packaging.

You may also be interested in...



Innovus Stretches Strongest Footprint With Boston Topicals Brands Deal

Innovus acquires Boston Topicals' ThermoMax hand warming cream in hot and warm formulations, BreastLife with amino acids to firm and lift women's breasts and HealthiFeet made with Knosis transdermal delivery system in a formulation firm says has been shown in a trial to increase temperature and blood flow in feet of diabetic patients. HealthiFeet will complement a product Innovus already offers and targets for consumers with diabetes, Diabases leg and foot relief topical.

Supplements More 'Mainstream' Than Alternative In Consumer Health Market

Sales of dietary supplements promoted as non-drug alternative remedies and stocked nearby OTC in stores grew almost 12% in 2017, says Kline analyst Laura Mahecha. Retailers began co-stocking the about five years ago but in many cases the supplements currently have primary placement on shelves.

Tech Transfer Roundup: Janssen, Eisai, Apexian, Innovus And More

Johnson & Johnson maintains hectic deal-making pace via RA tie-up with Monash and "diabesity" collaboration with UC San Diego.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS121156

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel